Dong-A Socio Holdings Co Ltd (000640) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
40
About the Report
About the Report
Summary
Dong-A Socio Holdings Co Ltd (Dong-A Socio Holdings), formerly Dong-A Pharmaceutical Co., Ltd., offers business management services. It is a subsidiary of Dong-A Socio Group. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group focuses on new business investments, development of biomedicines and research and development of new innovative drugs. Its main business areas include the manufacture of over-the-counter (OTC) and ethical drugs (ETC). Its major products include Bacchus-F, Bacchus-D, Panpyrin, Benachio, Myvlart Tab, Tempo and Eyebon. It also manufactures active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. Dong-A Socio Holdings is headquartered in Seoul, South Korea.
Dong-A Socio Holdings Co Ltd (000640)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Dong-A Socio Holdings Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Dong-A ST Extends Licensing Agreement with Eurofarma 12
Kaken Pharma Enters into Distribution Agreement with Dong-A ST 13
CrystalGenomics Enters into Agreement with Dong-A ST for Acelex 14
Dong-A ST Enters Into Co-Marketing Agreement With Huons For Nenoma 15
Licensing Agreements 16
Dong-A ST Enters into Licensing Agreement with Takara Bio 16
Neurobo Pharma Enters into Licensing Agreement with Dong-A ST 17
Rooyan Darou Pharma Enters into Agreement with Dong-A ST 18
Tabuk Pharma Enters into Licensing Agreement with Dong-A ST for Zydena 19
AbbVie Enters into Licensing Agreement with Dong-A ST 20
Dong-A ST Enters into Licensing Agreement with Beactica 21
ST Pharm Enters into Technology Transfer Agreement with KRICT 22
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 23
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 25
Geropharm Enters into Licensing Agreement with Dong-A ST 26
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 27
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 28
Sanwa Kagaku Kenkyusho Enters into Licensing Agreement with Dong-A ST 29
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 30
Equity Offering 31
ST Pharm to Raise USD113 Million in IPO 31
Dong-A Pharma Spin-Off Dong-A ST 32
Acquisition 33
Dong-A Socio to Acquire Shares of ST Pharm for USD157 Million in Tender Offer 33
Dong-A Socio to Divest Stake in DMB 34
Dong-A Pharmaceutical Mulling Acquisition of Spain's Invent Farma 35
Dong-A Socio Holdings Co Ltd-Key Competitors 36
Dong-A Socio Holdings Co Ltd-Key Employees 37
Dong-A Socio Holdings Co Ltd-Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Joint Venture 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Figure
List of Figures
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Dong-A Socio Holdings Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Dong-A Socio Holdings Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Dong-A ST Extends Licensing Agreement with Eurofarma 12
Kaken Pharma Enters into Distribution Agreement with Dong-A ST 13
CrystalGenomics Enters into Agreement with Dong-A ST for Acelex 14
Dong-A ST Enters Into Co-Marketing Agreement With Huons For Nenoma 15
Dong-A ST Enters into Licensing Agreement with Takara Bio 16
Neurobo Pharma Enters into Licensing Agreement with Dong-A ST 17
Rooyan Darou Pharma Enters into Agreement with Dong-A ST 18
Tabuk Pharma Enters into Licensing Agreement with Dong-A ST for Zydena 19
AbbVie Enters into Licensing Agreement with Dong-A ST 20
Dong-A ST Enters into Licensing Agreement with Beactica 21
ST Pharm Enters into Technology Transfer Agreement with KRICT 22
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 23
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 25
Geropharm Enters into Licensing Agreement with Dong-A ST 26
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 27
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 28
Sanwa Kagaku Kenkyusho Enters into Licensing Agreement with Dong-A ST 29
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 30
ST Pharm to Raise USD113 Million in IPO 31
Dong-A Pharma Spin-Off Dong-A ST 32
Dong-A Socio to Acquire Shares of ST Pharm for USD157 Million in Tender Offer 33
Dong-A Socio to Divest Stake in DMB 34
Dong-A Pharmaceutical Mulling Acquisition of Spain's Invent Farma 35
Dong-A Socio Holdings Co Ltd, Key Competitors 36
Dong-A Socio Holdings Co Ltd, Key Employees 37
Dong-A Socio Holdings Co Ltd, Subsidiaries 38
Dong-A Socio Holdings Co Ltd, Joint Venture 38
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.